Novartis is still in the game too, via ENTA's NS5a inhibitor, EDP-239: www.fiercebiotech.com/story/novartis-snags-preclinical-hep-c-drug-440m-enanta-pact/2012-02-21 Novartis snags preclinical hep C drug in $440M Enanta pact (Feb. 2012)